Why the study?
Does type 2 diabetes and glycemic control affect platelet reactivity post-clopidogrel therapy in patients undergoing coronary stent implantation?
Does type 2 diabetes and glycemic control affect platelet reactivity post-clopidogrel therapy in patients undergoing coronary stent implantation?
Type 2 diabetes and poor glycemic control are associated with higher post-clopidogrel platelet reactivity, which increases the risk of ischemic events after PCI.
Answers are grounded in this paper and cite their sources.
Elevated post-clopidogrel reactivity in diabetes may increase ischemic risk after PCI; leaves open whether glycemic control improves platelet response.
Platelet dysfunction contributes to the increased risk of thromboischemic complications after percutaneous coronary intervention (PCI), particularly in type 2 diabetes. Little is known about the effects of glycemic control on platelet reactivity. We assessed adenosine diphosphate-induced platelet aggregation and flow cytometric expression of P-selectin in 90 patients (56 diabetic and 34 nondiabetic patients) undergoing coronary stent implantation after administration of clopidogrel as a potential predictor of poststent complications and its relation to glycemic control. Posttreatment platelet reactivity was significantly elevated in diabetic compared with nondiabetic participants and was associated with smoking, hypercholesterolemia, overweight, and cardiovascular ischemic events. A linear relationship was found between hemoglobin A1c in diabetic patients and platelet reactivity. Both methods (standard aggregometry and P-selectin expression) used for assessment of platelet function were positively correlated. Low responsiveness to clopidogrel detected by posttreatment platelet reactivity is a risk factor for ischemic events after PCI in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: